Kerr Holbrook Sells 7,000 Shares of Avanos Medical, Inc. (NYSE:AVNS) Stock

Avanos Medical, Inc. (NYSE:AVNS) SVP Kerr Holbrook sold 7,000 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total transaction of $106,750.00. Following the completion of the transaction, the senior vice president now owns 82,047 shares in the company, valued at $1,251,216.75. The trade was a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Avanos Medical Stock Performance

Shares of Avanos Medical stock opened at $14.76 on Wednesday. The business’s fifty day simple moving average is $15.98 and its 200-day simple moving average is $19.18. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The firm has a market cap of $679.05 million, a PE ratio of 43.41 and a beta of 1.17. Avanos Medical, Inc. has a 52 week low of $14.40 and a 52 week high of $25.36.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.03. The company had revenue of $179.60 million during the quarter, compared to analyst estimates of $177.23 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. Equities analysts forecast that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Avanos Medical from a “buy” rating to a “hold” rating in a report on Tuesday.

Institutional Trading of Avanos Medical

Several institutional investors have recently added to or reduced their stakes in AVNS. T. Rowe Price Investment Management Inc. lifted its stake in Avanos Medical by 27.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock worth $47,941,000 after purchasing an additional 644,267 shares in the last quarter. Tributary Capital Management LLC raised its holdings in shares of Avanos Medical by 38.1% in the 4th quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock valued at $14,217,000 after buying an additional 246,379 shares during the period. Brown Advisory Inc. lifted its stake in Avanos Medical by 12.0% during the 4th quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock worth $30,329,000 after acquiring an additional 204,218 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Avanos Medical by 43.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock valued at $7,874,000 after acquiring an additional 148,902 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Avanos Medical by 189.8% in the 4th quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company’s stock valued at $3,210,000 after acquiring an additional 132,063 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.